News Release-- September 04, 2003

CSC - PORTON JOINT VENTURE WINS $11 MILLION AWARD TO EXPEDITE PRODUCTION OF BOTULINUM VACCINE

EL SEGUNDO, Calif., September 4, 2003 – Computer Sciences Corporation (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International Inc., has been awarded an $11 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for fast-track development of a heptavalent botulinum vaccine. Under this award, DVC plans to develop the manufacturing processes for a safe and efficacious vaccine that will protect against all known forms of botulinum neurotoxins within five years. These processes would then be available for transition into pilot lot manufacture of the vaccine prior to Phase I clinical testing.

“Botulinum neurotoxin is generally recognized as the deadliest naturally occurring substance known and has been identified as a potential bioweapon,” said DVC President Terry Irgens. “There is an urgent need for a safe, efficacious vaccine that will protect against all seven known serotypes of the neurotoxin.”

The NIAID award funds development of two botulinum vaccines. Within two years, DVC will expedite the manufacturing process development of a pentavalent vaccine designed to provide immunologic protection against botulinum neurotoxin serotypes A, B, C, E and F. Within five years, the company will also develop the manufacturing processes for a heptavalent vaccine that will include antigens designed to protect against botulinum neurotoxin serotypes D and G.

DVC Principal Investigator Ian Henderson, Ph.D., will lead the research efforts in the project. The University of Nebraska-Lincoln, Lincoln, Neb.; the University of Colorado Health Sciences Center, Denver, Colo.; HTD Biosystems Inc., Hercules, Calif.; and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Md., will team with DVC to provide research and manufacturing process development capabilities. USAMRIID owns the intellectual property for the vaccine to be produced and has filed patent applications.

NIAID is a component of the National Institutes of Health. NIAID conducts and supports research that strives to understand, treat and ultimately prevent the myriad infectious, immunologic and allergic diseases that threaten hundreds of millions of people worldwide. Since the fall of 2001, NIAID has greatly accelerated its biodefense research program, launching over 30 new research and construction initiatives. It has created a comprehensive strategic plan and a detailed research agenda for "Category A" agents of bioterrorism -- those considered by the Centers for Disease Control and Prevention to be the worst bioterror threats. These agents include smallpox, anthrax, the plague, botulism and the viral hemorrhagic fevers or "bleeding" fevers such as Ebola.

DVC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines. Founded in 1997, DVC employs 135 professionals at its headquarters in Frederick, Md. For more information about DVC, visit the company’s Web site at www.dynport.com.

DVC is part of CSC’s Enforcement, Security and Intelligence (ESI) organization, which CSC created in 2002 to support programs enhancing U.S. national security posture.

Porton International Inc. is a member of the Ipsen group of companies.

About CSC

Founded in 1959, Computer Sciences Corporation is a leading global IT services company. CSC’s mission is to provide customers in industry and government with solutions crafted to meet their specific challenges and enable them to profit from the advanced use of technology.

With approximately 92,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC’s own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in El Segundo, Calif., CSC reported revenue of $12.1 billion for the 12 months ended July 4, 2003. For more information, visit the company’s Web site at www.csc.com.